Shanghai JMT-Bio

Subsidiary of CSPC Pharmaceutical Group (1093)

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
EGFRMonoclonal antibody
Non-Small Cell Lung CancerColorectal Cancer
Phase 3
TSLPMonoclonal antibody
Chronic Obstructive Pulmonary DiseaseAsthma
Phase 1/2
β-Klotho (KLB)Monoclonal antibody
Cardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Phase 1/2
PD-1 and IL-15 receptorProtein / enzyme therapeutic
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
BecotatugPhase 3Local Advanced or Metastatic NSCLC
Est. primary completion 2027-03-26 · NCT06380348 · CT.gov ↗
What to watch
June 2027 (1)
BecotatugPhase 3Metastatic Colorectal Cancer (mCRC)
Est. primary completion 2027-06-01 · NCT07134205 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
SYS6090Phase 1/2Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2029-02-28 · NCT07472647 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 September 2026Topline resultJMT101 (becotatug)Phase 3 of becotatug plus osimertinib in EGFR exon 20 insertion NSCLC (NCT06380348) met its PFS primary endpoint at interim
CSPC Pharmaceutical Group Limited · Source ↗

Financial reports

No financial reports recorded.